FIGURE 3 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Year: 2024
Type: other
Abstract: Oncoplot showing mutations and co-occurring alterations in the patients enrolled in this clinical trial.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4391754877